Alnylam Pharmaceuticals

Alnylam controls the RNAi delivery bottleneck: its ESC-GalNAc conjugate chemistry (Enhanced Stabilization Chemistry Plus) is what makes liver-directed gene silencing clinically viable — turning a fragile, rapidly-degraded siRNA into a subcutaneous, quarterly-dosed drug with an 87% TTR knockdown at 2.5 years (Amvuttra Prescribing Information). Twenty-plus years of proprietary chemical-modification and conjugation data mean the delivery problem — not the target biology — is the moat. The commercial expression is the TTR-silencer toll-road: Amvuttra is the first and only TTR silencer (not merely stabilizer) approved for ATTR-CM, and after Ionis/AstraZeneca's eplontersen failed its CARDIO-TTRansform Phase 3 primary endpoint (Aug 2026), Amvuttra is now effectively the sole approved silencer for the full disease spectrum.

• ESC-GalNAc delivery chemistry — 87% TTR knockdown sustained at 2.5 years; quarterly SC dosing vs. tafamidis' daily oral. (Amvuttra PI; Q2 2026 8-K "About AMVUTTRA")
• Only full-spectrum TTR silencer — "the first and only silencer approved for the treatment of ATTR-CM and hATTR-PN." (Q2 2026 8-K)
• HELIOS-B mortality benefit — vutrisiran significantly reduced all-cause mortality and recurrent CV events in ATTR-CM; pooled >25,000 patient-year safety analysis at Heart Failure 2026. (JACC Apr 2025; HF 2026 data, Q2 2026 8-K)
• Six approved medicines, 20+ years proprietary RNAi data — the accumulated conjugation/chemistry dataset is the compounding asset, now being accelerated with the Inceptive foundation-model AI partnership. (Q2 2026 8-K)
• Pipeline breadth (the platform's optionality): zilebesiran (hypertension, Roche-partnered ZENITH Ph3), ALN-HTT02 (Huntington's, Ph1 readout Oct 23 2026), mivelsiran (Alzheimer's/CAA), ALN-6400 (von Willebrand), ALN-6222 (obesity), cemdisiran (gMG, Regeneron-partnered, FDA decision Nov 2026).

• product_service: RNAi therapeutics: Amvuttra, Onpattro, Givlaari, Oxlumo; partnered Leqvio. 10-K FY2024 Business (Acc. 0001178670-25-000016)
• technical function: Subcutaneous GalNAc-conjugated siRNAs target hepatocytes; RISC cleaves target mRNA, reducing disease-causing protein. 10-K FY2024 Business (Acc. 0001178670-25-000016)
• why it is hard: Proprietary GalNAc delivery, siRNA modifications, sequence design, manufacturing, broad IP estate, orphan exclusivity. 10-K FY2024 Business/Risk Factors (Acc. 0001178670-25-000016)
• substitutes: Antisense oligonucleotides, gene editing, small molecules, antibodies, protein replacement, TTR stabilizers. 10-K FY2024 Business/Risk Factors (Acc. 0001178670-25-000016)
• pricing power: HIGH — orphan/rare-disease pricing and payer coverage; limited direct RNAi competitors, though ATTR alternatives exist. 10-K FY2024 Risk Factors (Acc. 0001178670-25-000016)

• Does Amvuttra win first-line ATTR-CM share (vs. staying a second-line switcher), and what is the DETECT-ATTR screening yield in the 4.5M-member system? (answer: next 1–2 quarterly printouts + HFA 2027 data)
• What is the magnitude of the Amvuttra royalty obligation to partners (the driver of the COGS creep from 21.1% → 25.4%)? (answer: 10-K Note on collaborations/royalties)
• Will zilebesiran's ZENITH Phase 3 (hypertension) read out favorably, validating platform expansion beyond rare disease? (answer: ZENITH completion timing)
• Does in-vivo gene editing (a one-time cure) threaten the chronic RNAi dosing model before Amvuttra's franchise matures? (answer: monitor NTLA/BEAM/VERV clinical timelines)

INTACT. The TTR-silencer moat is intact and strengthened by eplontersen's Phase 3 failure (sole mortality-proven silencer), and ALNY is overtaking the tafamidis incumbent on ~75% growth. But the −28% drawdown correctly prices a launch-cadence reset: the finite second-line switching pool is absorbed, so the ramp now depends on first-line capture and diagnosis expansion (DETECT-ATTR). Moat ≠ a broken thesis; growth cadence is the open question.